<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-051961</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Janus® tacrolimus-eluting carbostent. Immediate and medium-term clinical results</dc:title>
<dc:description xml:lang="en">This observational and clinical follow-up study involved the first 50 patients who were treated with the Janus® tacrolimus-eluting carbostent (Sorin Group) at our hospital. The patients' mean age was 66 (10) years, 38% were diabetic, and 56% were admitted with acute coronary syndrome. In total, 56 lesions were treated (52% were type B2/C), of which 12% involved in-stent restenosis, 5% were chronic occlusions, 23% were long lesions (&gt;20 mm), 25% were in small vessels (&amp;#8804; 2.5 mm), 7% were aorto-ostial lesions, 5% were in vein grafts, and 14% involved angiographically visible thrombus. Some 63 Janus® carbostents were implanted (i.e., 1.26 [0.49] stents/patient). A successful outcome was achieved for all lesions. One patient (2%) required reintervention at the target lesion because of acute thrombosis. During a follow-up period of 10 (3) months, eight (16%) major adverse cardiac events occurred: there was one (2%) death due to heart failure and seven patients (14%) required revascularization, in five (10%) cases because of restenosis of the Janus® carbostent</dc:description>
<dc:creator>Rodríguez, Sergio</dc:creator>
<dc:creator>García-Tejada, Julio</dc:creator>
<dc:creator>Gutiérrez, Hipólito</dc:creator>
<dc:creator>Gómez, Iván</dc:creator>
<dc:creator>Hernández, Felipe</dc:creator>
<dc:creator>Albarrán, Agustín</dc:creator>
<dc:creator>Tascón, Juan</dc:creator>
<dc:creator>Velásquez, Teresa</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Estudio observacional con seguimiento clínico de los primeros 50 pacientes tratados en nuestro centro con el carbo-stent de tacrolimus Janus® (Sorin Group). La edad media de los pacientes fue 66 ± 10 años. El 38% era diabético y el 56% ingresó por un síndrome coronario agudo. Se trataron 56 lesiones (el 52% de tipo B2/C), incluidos un 12% de reestenosis intra-stent, un 5% de oclusiones crónicas, un 23% de lesiones difusas (&gt; 20 mm), un 25% de lesiones en vaso pequeño (&amp;#8804; 2,5 mm), un 7% de lesiones aortoostiales, un 5% de lesiones en puentes de safena y un 14% con trombo angiográfico. Se implantaron 63 carbo-stents Janus® (1,26 ± 0,49 stents/paciente). Se obtuvo éxito inmediato en todas las lesiones. Un paciente precisó reintervención de la lesión tratada por trombosis aguda (2%). Tras un seguimiento de 10 ± 3 meses se han producido 8 eventos adversos cardiacos mayores (16%): una muerte por insuficiencia cardiaca (2%) y 7 nuevos procedimientos de revascularización (14%), de los que 5 se debieron a reestenosis de carbo-stents Janus® (10%)</dc:description>
<dc:source>Rev Esp Cardiol;60(2): 197-200, feb. 2007. tab</dc:source>
<dc:identifier>ibc-051961</dc:identifier>
<dc:title xml:lang="es">Carbo-stent liberador de tacrolimus Janus®. Resultados inmediatos y seguimiento clínico a medio plazo</dc:title>
<dc:subject>^d28625</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24885</dc:subject>
<dc:subject>^d4405</dc:subject>
<dc:subject>^d36020^s22067</dc:subject>
<dc:subject>^d36021^s22067</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d33809^s22000</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d7344^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>200702</dc:date>
</metadata>
</record>
</ibecs-document>
